Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. by Toth, C. A. & Thomas, P.
Br. J. Cancer (1992). 65, 365 368 © Macmillan Press Ltd.. 1992
Type I interferon resistance in a colorectal cancer cell line is associated
with a more aggressive phenotype in vivo
C.A. Toth & P. Thomas
Laboratory ofCancer Biology, NVew England Deaconess Hospital, Harvard Medical School, Boston, Massachusetts 02115, l-SA.
Summary A type I interferon resistant variant (P-MIP101) of the poorly differentiated human colon cancer
cell MIPIOI has a more aggressive phenotype in vhvo in the nude mouse. Subcutaneous tumours grew at twice
the rate of MIPIOI. but with similar morphology. P-MIP101 also produced liver metastases at a higher
frequency. P-MIP101 tumours were diploid while MIPIOI tumours were aneuploid. Both cell fines had
doubling times of approximately 25 h in vitro.
Interferons are a family, of inducible proteins which can
mediate growth. differentiation and immunomodulation of
cells. Interferons are divided into three major classes (a. p
and y) based on cellular origin. biological function and
chemical properties. Interferons can mediate a host of cel-
lular responses by binding to cell surface receptors. x and P
interferon binds to type I receptors and y interferon interacts
with a separate receptor (type II) (Branca, 1988). Interferons
have cvtostatic effects on colorectal cancer cells both in vivo
and in vitro and can increase the expression of tumour
markers such as carcinoembrovonic antigen (CEA) (Toth &
Thomas, 1990 and Kondo et al.. 1987). The mechanism of
growth inhibition of transformed cells by interferons is un-
known.
Colorectal cancers are amongst the most difficult tumours
to treat once metastatic spread has occurred and are refrac-
tive to both chemotherapy and radiation therapy (Moertel.
1988; Steel & Thomas. 1988). The antiproliferative effects of
interferons make them potential antineoplastic agents. Clini-
cal trials of a and y interferon in combination with 5-
fluorouracil (5FUra) and tumour necrosis factor (TNF) in
metastatic colorectal cancer are currently underway (Wadler
et al.. 1990a; Abbruzzese et al., 1989: Ajani et al.. 1989).
As part of a study of the mechanisms of interferon action
on colorectal cancer cells, we have produced a clone of the
poorly differentiated colorectal carcinoma cell MIPlOI (Niles
et al.. 1987) that is resistant to the antiproliferative effects of
type I but not type II interferons. Determinations of the
differences between these resistant and sensitive cell lines may
assist in understanding these mechanisms, and allow better
utilisation of interferon therapy either alone or in conjunc-
tion with other treatments.
Materials and methods
Cell culture
MIPlOI and 1-MIP1IO were maintained in RPMI 1640
supplemented with heat inactivated foetal calf serum (10%).
L-glutamine, penicillin and streptomycin and screened for
mycoplasmal DNA by staining with Hoechst stain (Sigma
Chemical Co.).
Interferon
Recombinant human alpha interferon (Accurate Chemical.
Westbury, NY) and recombinant human gamma interferon
(AMGEN. Thousand Oaks, CA) had specific activities of
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1 x I0' IU mg-' of protein. Recombinant human beta inter-
feron (a gift from Triton Bioscience; Alameda. CA) had a
specific activity of 1.0 x 108IU ml' of protein.
Cellproliferation assav
Cells were plated in 24 well tissue culture dishes both in the
absence or presence of interferons. After 4 to 10 days de-
pending on the growth rate of the control samples. viable
cells were determined by hemocytometer counts following
harvesting with trypsin. The control (untreated) cells were
always <90% confluent and in log phase growth. Growth
measurements were determined in quadruplicate. Cell viabi-
litv was determined by trypan blue dye exclusion.
Tumorigenicitv assa!
Tumour cells were grown to subconfluency and detached
using EDTA (0.5 mM) in PBS. The cells were greater than
95%0 viable and no cell clumping was observed microscopic-
ally. Tumour cells (2 x 106) were injected subcutaneously in
the flank of nude mice to assess tumourigenicity. Growth was
monitored weekly and the final tumour weight determined at
autopsy. Tumours were fixed in 10% buffered formalin. para-
ffin embedded. processed routinely. and stained with haema-
toxylin and eosin.
Metastases assav
The formation of hepatic metastases by the tumour cell lines
were assessed using an intrasplenic injection model in
athymic nude mice (Wagner et al.. 1990). Briefly. the spleen
was exposed through a short incision and 2 x 106 cells in
100 t of PBS were slowly injected into its lower pole. The
spleen was replaced in the abdomen and the abdominal wall
and skin closed by clips.
Flow cvtometrv
Flow cy-tometric DNA quantitative analysis was performed
by the Nichols Institute (San Juan Capistrano. CA) using a
modification of the Krishan method (Dressler et al., 1988).
Six xenografts each of the resistant and sensitive cell lines
were excised, snap frozen and mechanically disassociated.
Subcellular debris were removed by centrifugation on a suc-
rose gradient. The cells were stained in a hypotonic pro-
pidium iodide buffer and the stained nuclei were analysed on
an EPIV V flow cytometer (Coulter Electronics. Hialeah.
FL).
Interferon uptake assays
P interferon (100fig) was labeled with 1 mCi of Na'25I to a
specific activity, of approximately 5 plCi Lg-' using the chlor-
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amine T procedure (Greenwood et al.. 1963). and ran as a
single band on 10% SDS-PAGE. Confluent monolayers of
MIPIOI and frMIP101 (1 x 106 cells) were incubated at 37°C
for 90 min with vanrous concentrations of '5I-P interferon in
PBS containing BSA (1 mg ml-'). The cells were washed
three times and solubilised in 1 M NaOH. The uptake of
frINF was determined by measuring the level of cell assoc-
iated '25I-P interferon. Nonspecific uptake was determined bv
measunrng '1I-P interferon uptake in the presence of a 250-
fold excess of unlabelled P interferon.
Results
We selected for a i interferon resistant variant of the poorlv
differentiated human colon carcinoma cell line MIPIOI. b;
culturing cells in the presence of 25.000 units ml-1 of recom-
binant human P interferon for 3 months. The 0 interferon in
the media was replenished every 7 days. The resulting cell
line frMIPIOI. was resistant to growth inhibition by P inter-
feron. Figure 1 shows the effects of i interferon on growth of
MIPIOI and frMIPIOI. The cells have remained resistant to
beta interferon without subsequent treatment for 2 years.
Figure 2 shows the effect a. i and y interferons on
MIPIOI and MIPIOI growth in vitro. Only the frMIPO1I
cells were resistant to a and B interferon. Neither cell line
was resistant to y interferon. Both the resistant and parent
cell lines had similar growth rates in *itro. The doubling time
for fi-MIPIOI was 23.8( ±3.1) h and for MIPIOI was 26.2
(± 5.0) h.
To study the potential changes in levels of type I receptors
between the two cell lines we used a binding assay with ''I
labelled fi interferon. Figure 3 shows no apparent difference
in the ability of MIPIOI and f-MIPIOI to internalise the
ligand.
Both cell lines were tumourigenic in nude mice. When they
were grown subcutaneously. the f-MIPIOI tumours grew-
more rapidly in vivo than the interferon sensitive MIP101
tumours (Figure 4). After 4 weeks the f-MIPIOI tumours
[1.1 g( ± 0.3)] were twice the size of the parental tumours
[0.5 g( ± 0.1)]. The data represent the average of 12 tumours
per cell line and the expenrment was performed twice with
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Figure 2 Effects of different interferons on cell growth. Grow-th
of tumours cells in v-itro. in the presence of interferon (2.500 U
m-'). Interferon was added on dav 1 and the rate of growth
determined after 5 davs. Solid bar= alpha interferon: Open bar
= beta interferon: Hatched bar= gamma interferon. Data are
expressed as growth of treated tumour cells as a percentage of the
controls (untreated cells). Data points represent the average of
triplicate samples and the error bars represent one standard
deviation.
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Figure 1 Effect of various concentrations of P interferon on
MIPIOI and f-MIPIOI growth. Growth of tumour cells in vitro.
in the presence of various concentrations of P interferon (1.000-
50.000 U ml-'). Interferon was added on day 1 and the rate of
growth determined after 5 days. Solid bar = MIPIOI: Open
bar = P-MIPI0O. Data are expressed as growth of treated tumour
cells as a percentage of the controls (untreated cells). Data point
represent the average of triplicate samples and the error bars
represent one standard deviation.
Figure 3 Uptake of P interferon by MIPlIO and f-MIPIOl.
IUptake of '"I l interferon (20-120 ng ml-') bv I x 106 cells after
90 min at 37C. Data points represent the average of triplicate
samples and error bars represent one standard deviation. The
variance between the cell lines was not statistically significant bv
ANOVA analysis. MIPIO - solid bar. f-MIPIOI - open bar.
comparable results. Examination of the sLx subcutaneous
tumours by flow cytometry showed the f-MIPIOI tumours
were diploid while the MIPIOI tumours were aneuploid,
Table I shows the cell cycle analysis. Histology of the xeno-
grafts showed both tumours to be poorly differentiated
adenocarcinomas of the colon neither of which produced
CEA.
Nude mice were examined 8 weeks after intrasplenic injec-
tion of MIPIOI tumour cells. Local tumour growth in the
spleen was observed in 6 15 (40%) of the mice with tumour
colonisation of the liver in only one animal (7%). With
P-MIPIOI cells tumour growth in the spleen occurred in 7 14
(50%) of the mice with tumour spread to the liver in 6 14
(43%) mice. The difference in local growth in the spleen was
not significant between the two groups, however, the number
of animals with hepatic tumours was significantly higher in
the f-MIPIOI group (P<0.05).
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Figure 4 Tumounrgenicity of B-MIPlO1 and MIPlOI. Tumour
growth by volume of MIPlIO and P-MIPl0 after subcutaneous
injection of 2 x 106 cells. B-MIPIOI - solid circle. MIPlOI - open
circle. Each data point represents the average of 12 tumours.
Error bars represent one standard deviation. Analysis of the data
using the ANOVA analysis of variance determined that for each
data point the difference between the cell lines was significant
(P<0.01).
Table I Cell cycle analysis of tumours by flow cytometry
DNA
Cell line Ploidr index Sphase %GOG1 %G.GM
MIP-101 I Aneuploid 2.00 12.6%o 78.60o 8.8°o
2 Aneuploid 1.95 26.0% 63.9°o 10.0°o
3 Aneuploid 1.95 20.3%o 75.0% 4.60o
4 Aneuploid 1.97 26.3%io 67.0% 6.20o
5 Aneuploid 1.96 30.8% o 50.20°o 18.80°o
6 Aneuploid 1.95 28.O,oo 52.60o 19.2°o
frMIPIO1 1 Diploid 1.00 27.8°o 59.8°o 12.20°o
2 Diploid 1.00 25.90°o 69.5° o 4.5°o
3 Diploid 1.00 28.1 ° o 54.80o 16.90o
4 Diploid 1.00 22.7%o 73.1Oo 4.0°o
5 Diploid 1.00 13.70o 83.9°o 2.30o
6 Diploid 1.00 23.9°o 67.80o 8.l°o
Long term i interferon treatment of the poorly differentiated
human colon cancer cell line (MIPIOI) resulted in a clone
(0-MIPO1I) which was resistant to the antiproliferative effects
of type I interferons. but retained its sensitivity to the effects
of type II interferon. Recently Morikawa et al. (1990) also
isolated interferon resistant clones from an interferon sensi-
tive human colorectal cancer cell line KM12C. They reported
that cells made resistant to a interferon became resistant to
both type I and type II interferons. However, cells made
resistant to type II interferons still showed sensitivity to type
I interferon.
In this study. the parent line MIPIOI shows some natural
resistance to the antiproliferative effects of P interferon (onlv
40% growth inhibition at 2.500 U ml-'. Figure 1). However.
this is not uncommon in colorectal cancer cell lines (Toth &
Thomas, 1990). Growth of the resistant clone. P-MIP101 was
not inhibited by P interferon at concentrations as high as
50,000 U ml', a level at which growth of the parent line
ceased. Both cell lines have similar growth rates in vitro in
the absence of interferon. However in vivo, 1-MIPIOI exhib-
ited a more aggressive phenotype, subcutaneously implanted
cells grew in the nude mouse at twice the rate of MIPIOI and
frMIPIOI produced significantly more liver metastases fol-
lowing intrasplenic injection than MIPIOI. Studies done with
several other poorly differentiated colorectal carcinomas have
shown that pretreatment of tumour cells with 0 interferon
prior to intrasplenic injection into nude mice resulted in
enhanced formation of hepatic metastases (Toth. 1990). The
dose of interferon used in clinical trials is comparable to an
in vitro concentration of less than 1,000 U ml-i. However, in
the liver both Kupffer and Ito cells secrete significant quanti-
ties of alpha and beta interferon in response to stimulus
resulting in a high concentration of interferon in the hepatic
sinusoid (Werner-Wasik et al., 1989; Chen et al.. 1989).
Secretion of interferon by these cells may play a role in the
control of hepatic metastases.
Metastases formation is a complex process involving a
number ofdifferent interactions between tumour cells and the
host. In this study we are dealing directly with tumour cell
changes mediated by interferon. Selection of the alpha and
beta interferon resistant subclone of the poorly differentiated
tumour cell line MIPIOI appears to have resulted in the
selection of cells with increased potential for formation of
hepatic metastases. It is unlikely that the metastases assay is
measuring just a difference in tumourigenicity between the
two cell lines. Both cell lines showed the same degree of
splenic tumour growth, however there was a significant
difference in the incidence of hepatic tumours. The mechan-
ism which results in enhanced hepatic metastases formation
remains unknown. However, we know from other studies
being conducted in our laboratory that it is unlikely that
altered resistance to NK activity and hepatic macrophage
cytotoxicity is the cause since MIPIOI is resistant to the
cytotoxic effects of nude mouse NK and Kupffer cells
(unpublished results, Jessup & Toth; Meterrisian & Toth).
Colorectal cancer patients have a low response rate to a
and P interferons as a single therapeutic agent in clinical
trials (Eggermont et al.. 1985: Lillis et al.. 1987). Interferons
when used in combination with 5-FUra and TNF have
shown enhanced antitumour effects against colorectal cancers
in preclinical studies (Schiller et al.. 1990; Wadler et al..
1990b). Clinical trials using alpha and gamma interferon in
combination with 5FUra are underway as are studies with
TNF (Wadler et al.. 1990c; Abbruzzese et al.. 1989). Treat-
ment of colorectal cancer patients with alpha interferon and
5FUra has shown promising results (Wadler et al.. 1990a). In
vitro, the Type I interferons appear to be more potent modu-
lators of 5FUra cytotoxicity when compared to Type II
(Wadler et al.. 1990b). Since little is known about Type I
interferon resistance in colorectal tumours these cell lines
should prove useful. In addition they may be employed in
investigations of the mechanisms of type I interferon induced
antiproliferation and for studies investigating mechanisms of
hepatic metastases formation.
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